Upcoming Webinar
Discussion of zanubrutinib (BRUKINSA®) for Adult Patients with CLL/SLL
Date: October 31, 2025 | 2:00 PM
When: Friday, October 31 | 2 p.m. EST
Presenters: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC | Minnesota Oncology
For patients who can’t tolerate ibrutinib or acalabrutinib, what’s next?
Kirollos Hanna takes a practical look at where zanubrutinib fits in the evolving treatment of CLL and SLL. He’ll share insights from Study 215, including how patients previously intolerant to other BTK inhibitors responded, and review updated safety comparisons between zanubrutinib and acalabrutinib.
Key Learnings:
- How to interpret new efficacy and safety data in context of real-world patient management
- What clinicians should know about dosing adjustments and AE prevention
- Practical strategies for managing hypertension, bleeding, and cardiac risk during treatment
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
October 31, 2025 | 2:00 PM
November 3, 2025 | 2:00 PM
Upcoming Webinar
Applying the NCODA PQI: Encorafenib + Cetuximab + mFOLFOX6 for BRAF V600E–Mutated mCRC
November 6, 2025 | 2:00 PM